Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shu-Zheng Lyu"'
Publikováno v:
Cardiovascular Therapeutics, Vol 2020 (2020)
Objective. This prospective study aimed to evaluate the value of the cardiac cycle time-corrected electromechanical activation time (EMATc) measured at admission for predicting major cardiac adverse events (MACEs) in hospitalized patients with chroni
Externí odkaz:
https://doaj.org/article/b4586a8948e542d580abdba0a9e155f6
Publikováno v:
Chinese Medical Journal, Vol 131, Iss 5, Pp 600-607 (2018)
Background: Currently, drug-eluting balloon (DEB) appears to be an attractive alternative option for the treatment of in-stent restenosis (ISR). Nevertheless, the clinical outcomes of DEB have seldom been compared to those of new-generation drug-elut
Externí odkaz:
https://doaj.org/article/017c36543942448492b1ea2ec74e2799
Autor:
Xian-Peng Yu, Chang-Yan Wu, Xue-Jun Ren, Fei Yuan, Xian-Tao Song, Ya-Wei Luo, Ji-Qiang He, Yue-Chun Gao, Fang-Jiong Huang, Cheng-Xiong Gu, Li-Zhong Sun, Shu-Zheng Lyu, Fang Chen
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 7, Pp 763-770 (2016)
Background: There are limited data on longer-term outcomes (>5 years) for patients with unprotected left main coronary artery (ULMCA) disease who underwent percutaneous coronary intervention (PCI) in the drug-eluting stents (DES) era. This study aime
Externí odkaz:
https://doaj.org/article/5a0ce5cb837e40afa0e4152e172bdb75
Autor:
Ji-Qiang He, Xian-Peng Yu, Cheng Peng, Quan Li, Ya-Wei Luo, Yue-Chun Gao, Xiao-Ling Zhang, Chang-Yan Wu, Hua Zhao, Yu-Chen Zhang, Jing-Hua Liu, Shu-Zheng Lyu, Fang Chen
Publikováno v:
Chinese Medical Journal, Vol 128, Iss 16, Pp 2176-2182 (2015)
Background: The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery Score II (SS-II) can well predict 4-year mortality in patients with complex coronary artery disease (CAD), and guide decision-making between coronary ar
Externí odkaz:
https://doaj.org/article/66285884ed0547d992930cd6880244c7
Autor:
Wei, Wang, Xian-Tao, Song, Yun-Dai, Chen, Fei, Yuan, Feng, Xu, Min, Zhang, Kai, Tan, Xing-Sheng, Yang, Xian-Peng, Yu, Kong-Yong, Cui, Shu-Zheng, Lyu
Publikováno v:
Journal of Geriatric Cardiology : JGC
Background Growth differentiation factor-15 (GDF-15) is involved in multiple processes that are associated with coronary artery disease (CAD). However, little is known about the association between GDF-15 and the future ischemic events in patients wi
Autor:
Kong-Yong, Cui, Shu-Zheng, Lyu, Xian-Tao, Song, Fei, Yuan, Feng, Xu, Min, Zhang, Ming-Duo, Zhang, Wei, Wang, Dong-Feng, Zhang, Jing, Dai, Jin-Fan, Tian, Yun-Lu, Wang
Publikováno v:
Journal of Geriatric Cardiology : JGC
Background It is still controversial whether percutaneous coronary intervention with drug-eluting stent (DES) is safe and effective compared to coronary artery bypass graft surgery (CABG) for unprotected left main coronary artery (ULMCA) disease at l
Autor:
Jing, Dai, Shu-Zheng, Lyu, Yun-Dai, Chen, Xian-Tao, Song, Min, Zhang, Wei-Min, Li, Yang, Zheng, Shang-Yu, Wen, Shao-Ping, Nie, Yu-Jie, Zeng, Hai, Gao, Yi-Tong, Ma, Shu-Yang, Zhang, Li-Jun, Guo, Zheng, Zhang
Publikováno v:
Journal of Geriatric Cardiology : JGC
Background The benefit/risk ratio of stenting in acute ST-segment elevation myocardial infarction (STEMI) patients with single vessel intermediate stenosis culprit lesions merits further study, therefore the subject of the present study. Methods and
Autor:
Wei, Wang, Xian-Tao, Song, Yun-Dai, Chen, Xing-Sheng, Yang, Feng, Xu, Min, Zhang, Kai, Tan, Fei, Yuan, Dong, Li, Shu-Zheng, Lyu
Publikováno v:
Journal of Geriatric Cardiology : JGC
Background This prospective study integrated multiple clinical indexes and inflammatory markers associated with coronary atherosclerotic vulnerable plaque to establish a risk prediction model that can evaluate a patient with certain risk factors for
Autor:
Dong-Feng, Zhang, Xian-Tao, Song, Yun-Dai, Chen, Fei, Yuan, Feng, Xu, Min, Zhang, Ming-Duo, Zhang, Wei, Wang, Jing, Dai, Shu-Zheng, Lyu
Publikováno v:
Journal of Geriatric Cardiology : JGC
Background Interleukin (IL)-10, IL-6 and their ratio (IL-6/IL-10) play an important role in the risk of developing coronary artery disease, and may correlate with its outcomes. Few clinical trials have investigated the prognostic impact of these fact